Two repeated low doses of doxorubicin are more effective than a single high dose against tumors overexpressing P-glycoprotein

Cancer Letters

Volumn 360, Issue 2, 2015, Pages 219-226

  Riganti, Chiara ^a   Gazzano, Elena ^a   Gulino, Giulia Rossana ^a   Volante, Marco ^b   Ghigo, Dario ^a   Kopecka, Joanna ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Doxorubicin; Mitochondria; P glycoprotein; Reactive oxygen species

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CASPASE 3; CASPASE 9; CREATINE KINASE; CREATININE; CYTOCHROME C; DOXORUBICIN; LACTATE DEHYDROGENASE; MULTIDRUG RESISTANCE PROTEIN; REACTIVE OXYGEN METABOLITE; ANTINEOPLASTIC ANTIBIOTIC;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL EFFECTIVENESS; COLON CANCER; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG TREATMENT FAILURE; ELECTRON TRANSPORT; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; OXIDATION; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REPEATED DRUG DOSE; SINGLE DRUG DOSE; TREATMENT DURATION; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; COLONIC NEOPLASMS; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; HT 29 CELL LINE; LUNG NEOPLASMS; METABOLISM; MITOCHONDRION; OXIDATIVE STRESS; RANDOMIZATION;

MURINAE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CASPASE 3; CASPASE 9; COLONIC NEOPLASMS; CYTOCHROMES C; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; HT29 CELLS; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MITOCHONDRIA; OXIDATIVE STRESS; P-GLYCOPROTEIN; RANDOM ALLOCATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84924911439     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.02.008     Document Type: Article

References (38)

1. Nars M.S., Kaneno R. Immunomodulatory effects of low dose chemotherapy and perspectives of its combination with immunotherapy. Int. J. Cancer 2013, 132:2471-2478.
2. Ahn K., Luo J., Berg A., Keefe D., Wu R. Functional mapping of drug response with pharmacodynamic-pharmacokinetic principles. Trends Pharmacol. Sci 2010, 31:306-311.
3. Clayton F., Tessnow K.A., Fang J.C., Holden J.A., Moore J.G. Circadian variation of topoisomerase II-alpha in human rectal crypt epithelium: implications for reduction of toxicity of chemotherapy. Mod. Pathol 2002, 15:1191-1196.
4. Kang T.H., Sancar A. Circadian regulation of DNA excision repair: implications for chrono-chemotherapy. Cell Cycle 2009, 8:1665-1667.
5. Andre N., Padovani L., Pasquier E. Metronomic scheduling of anticancer treatment: the next generation of multitarget therapy?. Future Oncol 2011, 7:385-394.
6. Pasquier E., Kavallaris M., Andre N. Metronomic chemotherapy: new rationale for new directions. Nat. Rev. Clin. Oncol 2010, 7:455-465.
7. Gholam D., Giacchetti S., Brézault-Bonnet C., Bouchahda M., Hauteville D., Adam R., et al. Chronomodulated irinotecan, oxaliplatin, and leucovorin-modulated 5-Fluorouracil as ambulatory salvage therapy in patients with irinotecan- and oxaliplatin-resistant metastatic colorectal cancer. Oncologist 2006, 11:1072-1080.
8. Santini D., Vincenzi B., La Cesa A., Caricato M., Schiavon G., Spalletta B., et al. Continuous infusion of oxaliplatin plus chronomodulated capecitabine in 5-fluorouracil- and irinotecan-resistant advanced colorectal cancer patients. Oncology 2005, 69:27-34.
9. Tang T.C., Man S., Xu P., Francia G., Hashimoto K., Emmenegger U., et al. Development of a resistance-like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic UFT chemotherapy. Neoplasia 2010, 12:928-940.
10. Emmenegger U., Francia G., Chow A., Shaked Y., Kouri A., Man S., et al. Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide. Neoplasia 2011, 13:40-48.
11. Igarashi T., Izumi H., Uchiumi T., Nishio K., Arao T., Tanabe M., et al. Clock and ATF4 transcription system regulates drug resistance in human cancer cell lines. Oncogene 2007, 26:4749-4760.
12. Kubisch R., Meissner L., Krebs S., Blum H., Günther M., Roidl A., et al. A comprehensive gene expression analysis of resistance formation upon metronomic cyclophosphamide therapy. Transl. Oncol 2013, 6:1-9.
13. Martin-Padura I., Marighetti P., Agliano A., Colombo F., Larzabal L., Redrado M., et al. Residual dormant cancer stem-cell foci are responsible for tumor relapse after antiangiogenic metronomic therapy in hepatocellular carcinoma xenografts. Lab. Invest 2012, 92:952-966.
14. Gottesman M.M., Fojo T., Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2002, 2:48-58.
15. Kopecka J., Campia I., Olivero P., Pescarmona G., Ghigo D., Bosia A., et al. A LDL-masked liposomal-doxorubicin reverses drug resistance in human cancer cells. J. Contr. Rel 2011, 149:196-205.
16. Lee B.D., French K.J., Zhuang Y., Smith C.D. Development of a syngeneic in vivo tumor model and its use in evaluating a novel P-glycoprotein modulator, PGP-4008. Oncol. Res 2003, 14:49-60.
17. Riganti C., Miraglia E., Viarisio D., Costamagna C., Pescarmona G., Ghigo D., et al. Nitric oxide reverts the resistance to doxorubicin in human colon cancer cells by inhibiting the drug efflux. Cancer Res 2005, 65:516-525.
18. Freyria F.S., Bonelli B., Tomatis M., Ghiazza M., Gazzano E., Ghigo D., et al. Hematite nanoparticles larger than 90 nm show no sign of toxicity in terms of lactate dehydrogenase release, nitric oxide generation, apoptosis, and comet assay in murine alveolar macrophages and human lung epithelial cells. Chem. Res. Toxicol 2012, 25:850-861.
19. Harasym T.O., Cullis P.R., Bally M.B. Intratumor distribution of doxorubicin following i.v. administration of drug encapsulated in egg phosphatidylcholine/cholesterol liposomes. Cancer Chemother. Pharmacol 1997, 40:309-317.
20. Campia I., Lussiana C., Pescarmona G., Ghigo D., Bosia A., Riganti C. Geranylgeraniol prevents the cytotoxic effects of mevastatin in THP-1 cells, without decreasing the beneficial effects on cholesterol synthesis. Br. J. Pharmacol 2009, 158:1777-1786.
21. Riganti C., Aldieri E., Bergandi L., Tomatis M., Fenoglio I., Costamagna C., et al. Long and short fiber amosite asbestos alters at a different extent the redox metabolism in human lung epithelial cells. Toxicol. Appl. Pharmacol 2003, 193:106-115.
22. Riganti C., Voena C., Kopecka J., Corsetto P.A., Montorfano G., Enrico E., et al. Liposome-encapsulated doxorubicin reverses drug resistance by inhibiting P-glycoprotein in human cancer cells. Mol. Pharm 2011, 8:683-700.
23. Riganti C., Salaroglio I.C., Pinzòn-Daza M.L., Caldera V., Campia I., Kopecka J., et al. Temozolomide down-regulates P-glycoprotein in human blood-brain barrier cells by disrupting Wnt3-signalling. Cell. Mol. Life Sci 2014, 71:499-516.
24. Liu L., Dahlgren C., Elwing H., Lundqvist H. A simple chemiluminescence assay for the determination of reactive oxygen species produced by human neutrophils. J. Immunol. Methods 1996, 192:173-178.
25. Ottewell P.D., Mönkkönen H., Jones M., Lefley D.V., Coleman R.E., Holen I. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J. Natl. Cancer Inst 2008, 100:1167-1178.
26. Ottewell P.D., Lefley D.V., Cross S.S., Evans C.A., Coleman R.E., Holen I. Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model. Int. J. Cancer 2010, 126:522-532.
27. De Boo S., Kopecka J., Brusa D., Gazzano E., Matera L., Ghigo D., et al. iNOS activity is necessary for the cytotoxic and immunogenic effects of doxorubicin in human colon cancer cells. Mol. Cancer 2009, 8:e108.
28. To H. Construction of combined chemotherapy of anti-tumor drugs based on chronotherapy. Yakugaku Zasshi 2006, 126:415-422.
29. Manso L., Valdiviezo N., Sepulveda J., Ciruelos E., Mendiola C., Ghanem I., et al. Safety and efficacy of metronomic non-pegylated liposomal encapsulated doxorubicin in heavily pretreated advanced breast cancer patients. Clin. Transl. Oncol 2013, 15:467-471.
30. Munzone E., Di Pietro A., Goldhirsch A., Minchella I., Verri E., Cossu-Rocca M., et al. Metronomic administration of pegylated liposomal-doxorubicin in extensively pre-treated metastatic breast cancer patients: a mono-institutional case-series report. Breast 2010, 19:33-37.
31. Klement G., Huang P., Mayer B., Green S.K., Man S., Bohlen P., et al. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clin. Cancer Res 2002, 8:221-232.
32. Simunek T., Sterba M., Popelova O., Adamcova M., Hrdina R., Gersl V. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol. Rep 2009, 61:154-171.
33. Mailloux R.J., Harper M.E. Mitochondrial proticity and ROS signaling: lessons from the uncoupling proteins. Trends Endocrinol. Metab 2012, 23:451-458.
34. Marcillat O., Zhang Y., Davies K.J. Oxidative and non-oxidative mechanisms in the inactivation of cardiac mitochondrial electron transport chain components by doxorubicin. Biochem. J. 1989, 259:181-189.
35. Strigun A., Wahrheit J., Niklas J., Heinzle E., Noor F. Doxorubicin increases oxidative metabolism in HL-1 cardiomyocytes as shown by 13C metabolic flux analysis. Toxicol. Sci 2012, 125:595-606.
36. Indran I.R., Tufo G., Pervaiz S., Brenner C. Recent advances in apoptosis, mitochondria and drug resistance in cancer cells. Biochim. Biophys. Acta 2011, 1807:735-745.
37. Harper M.E., Antoniou A., Villalobos-Menuey E., Russo A., Trauger R., Vendemelio M., et al. Characterization of a novel metabolic strategy used by drug-resistant tumor cells. FASEB J. 2002, 16:1550-1557.
38. Pluchino K.M., Hall M.D., Goldsborough A.S., Callaghan R., Gottesman M.M. Collateral sensitivity as a strategy against cancer multidrug resistance. Drug Resist. Updat 2012, 15:98-105.